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Hereditary hemochromatosis (HH) is a not uncommon auto-
somal recessive and potentially life-threatening disease. The 
hemochromatosis gene was identified by Feder et al. in 1996. 
About 1 in 200 individuals is estimated to be homozygous for 
the most common mutation—C282Y/C282Y. In the classi-
cal form of the disease, cysteine is substituted by tyrosine at 
amino acid 282 in both alleles. The so-called compound het-
erozygoty is less common (representing about 10% of cases) 
but is also compatible with HH. Here, histidine is substituted 
by aspartic acid at amino acid 63 in one allele and cysteine by 
tyrosine at amino acid 282 in the other (C282Y/H63D). 
Due to increased intestinal absorption, homozygotes develop 
iron overload but penetrance is very variable (McCune et al. 
2006). Most orthopedic surgeons meet patients with undiag-
nosed HH on a yearly basis and an early diagnosis and treat-
ment is important in order to avoid cirrhosis of the liver. Also, 
the risk of developing hepataocellular cancer is at least 20-
fold higher than in their first-degree relatives (Elmberg et al. 
2003). Fatigue and arthritis, unspecific and therefore often 
neglected,  are  common  presentations  whereas  the  classic 
bronze diabetes (darkened skin, diabetes, and cirrhosis) is the 
final stage of untreated HH that is very rarely seen (McDonell 
et al. 1999). 
A survey of 2,851 patients with hemochromatosis showed 
that patients had consulted a physician after an average of 2 
years of symptoms, and on average it took a further 10 years 
before the diagnosis was made (McDonell et al. 1999). This 
is unfortunate, since medical treatment—i.e. regular phlebot-
omy—is effective. 
During the period 2001–2008, I replaced 93 ankles in 86 
patients and 4 of these patients proved to have hemochroma-
tosis. Here I have reviewed the orthopedic manifestations in 
7 patients who had one or both ankles replaced during this 
period, 3 of whom had had their ankles replaced elsewhere. 
Cases
The original records from all orthopedics departments and 
units  of  gastroenterology  involved  were  consulted  and  the 
author interviewed the patients at least twice. 
All  but  1  patient  were  below  the  age  of  45  when  they 
had their first joint symptoms, and there was usually a long 
patient’s and doctor’s delay before diagnosis and treatment. 
In 4 cases the hip, knee or ankle joint, and not the MP joints, 
was the first joint to become symptomatic. Only in one case 
(patient 5) did the joint symptoms start after the time that the 
diagnosis of HH had been made (Table 1).
4 patients (cases 1–4) had been referred to me from other 
hospitals due to painful osteoarthrosis of one or both ankles. 
In 3 of these cases, the diagnosis had been made before refer-
ral by laboratory testing and liver biopsy but the genotype was 
determined at referral.
In patient 3, I suspected and confirmed the diagnosis. She 
proved  to  have  a  compound  heterozygoty  (C282Y/H63D). 
The patient had donated blood regularly, which explains her 
only modestly increased laboratory values. 3 other patients 
with HH (cases 5–7) who had been operated on for a total 
ankle prosthesis elsewhere were identified via the Swedish 
National Board of Health and Welfare. The correct diagnosis 
had been reported to the Swedish Ankle Arthroplasty Register 
(Henricson et al. 2007) in only one of these 3 cases.
 None of the patients had reported any major ankle trauma. 
Preoperative radiographs of all ankles that had been replaced, 
and the as yet unreplaced ankles in cases 5 and 6, were scru-
tinized. The radiographic pattern was uniform, with reduction 
of the joint space, bony eburnation, cysts in the distal tibia 
and/or talus, and osteophytes. The latter were always located 
anteriorly at the neck of the talus and distal tibia, but some-
times also posteriorly. With few exceptions, the reduction of 
the joint space was located laterally and always anteriorly. 372  Acta Orthopaedica 2009; 80 (3): 371–374
Discussion
Joint  complaints  are  one  of  the  most  frequent  symptoms 
of HH and they are often the first clinical manifestation of 
disease (McDonell et al. 1999, Inês et al. 2001, von Kempis 
2001, Rihl and Kellner 2004). Although cirrhosis of the liver 
and cancer are important for mortality in patients with HH, 
arthropathy  has  the  greatest  effect  on  quality  of  life  (von 
Kempis 2001). 
The mechanism behind the arthropathy in HH is unknown. 
In  HH,  the  sensitivity  to  cartilage  damage  is  presumably 
increased and/or reparative capacity is reduced (Huch et al 
1997). In most studies, no correlation has been found between 
serum ferritin levels and arthropathy. In contrast to other man-
ifestations of the disease, the joint symptoms do not diminish 
after phlebotomy, or if so, only to a minor degree (Adams et 
al 1997, Sinigaglia et al 1997, McDonell et al. 1999, Rihl and 
Kellner 2004). Valenti et al. (2008) have, however, reported 
Table 1. Demographic data, laboratory findings, and joints replaced in 7 patients with hereditary hemochromatosis
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P
 
1  F  C282Y/   45  56    84%  4115     30  MCP c and   15  R+L   –  L 55  4
    C282Y              finger joints    54    R 58 
2  M  C282Y/  53  61   100%   >1,900      40    knee   13   61   60   R 60  4
      C282Y                      L 61
3    F   C282Y/  48  48     69%   241   b    25   hip   13   38  –  R 48   2
    H63D  38           
4   F  C282Y/     62   71   Missing   1,426      52   MCP-joints c   10  –  R 66  L 71  3 
    C282Y                      R 72 
5   M  C282Y/    40   45     87%   3,200      45    knee and    –   –   –   R 57  1 +  2 knees 
    C282Y               ankle          HTO R+Ld  1 ankle 
6   M  C282Y/    42 a  42 a  100%   2,456      20   multiple  22  –   –   R 49  1
    C282Y                 joint symptoms              1   1 ankle
7   M  C282Y/    44  44     99%   8,900      43    ankle     1   –    –   R 49   1  
    C282Y 
Mean    48   52     94%    3,666    36      12    
value        (n = 5)  (n = 6)
 
A  Case No.  
B  Sex      
C Genotype  
D Age when diagnosis was confirmed clinically 
  a When starting as a blood donor    
E  Age when diagnosis was confirmed genetically 
  a When starting as a blood donor      
F  Transferrin saturation before treatment    
G Serum ferritin (μg/L) before treatment 
  (Normal range: females 10–220 μg/L, males 25–400 μg/L) 
H Comment 
Case no 2. The right ankle preoperatively. 
This man had his right ankle and left knee 
replaced during the same anesthesia, at 
the age of 60. The following year his left 
ankle  and  right  hip  were  replaced,  also 
during  the  same  anaesthesia.  Pain  and 
swelling of the knee started at the age of 
40, but 13 years later it was first confirmed 
that  he  suffered  from  hemochromatosis. 
The  ankles  became  symptomatic  at  the 
age of 42. Reduction of the joint space is 
seen anteriorly and laterally and there are 
osteophytes, notably anteriorly at the neck 
of the talus and distal tibia. Bony eburna-
tion and cysts in the talus and distal tibia 
can also be seen. 
  B   A
  b Already blood donor when diagnosis was confirmed
I  Age at onset of joint symptoms 
J  Initial joint location
  c MCP: metacarpophalangeal joints 
K  Delay in diagnosis (years) 
L  Total hip replacement (age)
M Total knee replacement (age)
N Total ankle replacement (age9
O Number of joints replaced
  d HTO: High tibial osteotomy
P  No. of joints planned to be replacedActa Orthopaedica 2009; 80 (3): 371–374  373
that 32 of 88 patients with phenotypically expressed HH had 
radiographically verified changes in the metacarpophalangeal 
(MCP) joints, and that the severity of these changes was influ-
enced by the degree of iron overload. 
In textbooks and most papers on HH, symptoms from—
and radiographic changes in—the MCP joints are repeatedly 
described as typical for the disease, whereas little or no atten-
tion has been drawn to other joints. The reason for this is pre-
sumably that degenerative changes of other joints are much 
more common and cannot be distinguished from those that 
occur in HH.
 Whether or not major joints (i.e. the hip, knee, ankle, shoul-
der, and elbow) are affected more often in HH than in the gen-
eral population is unclear. Lunn et al. (2005) found 2 out of 
116 patients who had undergone primary hip replacement to 
be C282Y homozygotes—a figure that is similar to the preva-
lence in the general population of Ireland. Curiously enough, 
substantially more patients—10 of 101 patients—who under-
went revision of their hip were C282Y homozygotes. In a large 
population study, Adams et al. (2005) only found self-reported 
arthritis to be more common in males who were homozygous 
for H63D than in participants without HFE mutations. Walker 
et  al.  (2006)  demonstrated  an  association  between  geno-
type and interleukin 1 receptor antagonist (IL1RN) levels in 
patients with HH and joint pain. Axford et al. (1991) described 
an increased incidence of hip involvement, and Rollot et al. 
(2005) suggested that osteonecrosis of the femoral head may 
be one expression of HH. 
My  observations  and  those  of  a  few  others  (Bayley  and 
Gardner 1998, Jacki et al. 1999, Schmid et al. 2003, Davies 
and Saxby 2006) indicate that the ankle may also be a key joint 
in HH. In the literature, I have found 5 papers that together 
reported on 13 patients who had had one ankle replaced and 
3 papers that reported on HH patients who had had their hip 
joint replaced (Table 2). Here I report on another 7 patients 
who had 10 ankles and 6 other major joints replaced. 
For  unknown  reasons,  the  ankle  is  less  susceptible  to 
osteoarthritis  than  the  knee  and  hip,  and  symptomatic 
osteoarthritis  of  the  ankle  is  uncommon  even  at  advanced 
age. 
All the patients in my study had one or two ankles replaced, 
and all but one patient also had at least one other joint that 
was replaced or diseased. Recently, Carroll (2006) reported 
a strong and statistically significant association between HFE 
gene mutations and primary OA in the ankle joint. Due to the 
frequent presence of OA of the second and third MCP joint in 
these patients, the same author also suggested the existence of 
a type-2 polyarticular OA phenotype that closely resembles 
the arthropathy of HH, which appears to be clinically differen-
tiable from a type-1 OA or nodal generalized OA (NGOA).
There do not seem to be any radiographic phenomena that 
are typical of HH except for the reduction of joint space, bony 
eburnation, and broadening of the metacarpal heads seen in 
the MCP joints. This differs from what is usually seen in other 
types of arthritis.
The MRI appearance of arthropathy in HH cannot be distin-
guished from that of other types of degenerative osteoarthritis; 
the  method  cannot  demonstrate  the  presence  of  iron  in 
synovium, synovial fluid, or cartilage. It may be that the iron 
is below the threshold of detection by existing MRI techniques 
(Jager et al. 1997, Papakonstantinou et al. 2005). At surgery, 
the 7 ankles replaced by myself (cases 1–4) had the same 
appearance as in ordinary, degenerative osteoarthritis. In cases 
2 and 4, the resected joint parts were examined histologically. 
No traces of iron were found. 
The presence of long-standing joint pain and/or osteoarthritis 
in a person below the age of 55–60 years should thus arouse 
suspicion of HH if the symptoms cannot be related to another 
specific disease, e.g. seropositive rheumatoid arthritis, psoria-
sis, or arthritis urica. If more than one major joint is involved—
notably bilateral ankle arthropathy without previous trauma—
the suspicion is strengthened (Davies and Saxby 2006).
In such cases, plasma or serum iron levels, total iron-bind-
ing capacity (TIBC), and serum ferritin should be analyzed. 
An iron-saturation level (Fe/TIBC × 100) above 50% or an 
increased ferritin value should be followed by genetic testing. 
Table 2. HH and joint replacement as reported in the literature
First author  Year of   No. of   No. of   Thereof   No. of   No. of   Total no.   Comments
  publication  patients  hips  with AVN  knees  ankles  of joints
Jarde et al.  1977  1   –   –   –   1  ≥ 1  A series of failed ankle prostheses
Montgomery et al.  1988   15  19  7  –   –  19  Case series
Hinterman   1999   2  –   –   –   2   –   A medium-term analysis of ankle   
                prostheses
McDonell et al.   1999  109  –   –   –    –  >109  A survey of 2,851 HH patients
Lecoules et al.  2002  3    3         3  Case series
Davies and Saxby  2006  4  –  –   –   4  –  Case series
Fevang et al.   2007   4  –  –   –  4  –   Report from national register
Hosman et al.   2007   2  –  –   –   2  –  Report from national register
Own cases    7   4  ?  2  10   16  Case series
– : not stated; AVN: avascular necrosis.
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If this confirms that the patient is homozygous, or has a so-
called compound heterozygoty for HH, the individual should 
be referred to a gastroenterologist for further examination. 
Joint symptoms do not appear to be influenced by early diag-
nosis and treatment, but awareness of the condition and posi-
tive screening may prevent patients and their relatives from 
undergoing the more serious consequences of HH by regular 
phlebotomy. 
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